Aethlon Medical, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended March 31, 2021, compared with fiscal year ended March 31, 2020. Although the request metadata says “2020 Q4,” this filing is an annual report for FY2021, not a quarterly filing.
Business context
Aethlon is a clinical-stage medical technology company developing the Hemopurifier, an extracorporeal device intended to remove tumor-derived exosomes and certain viruses from blood. Its majority-owned subsidiary, Exosome Sciences, develops exosome-based diagnostic biomarkers. The company had no commercial product sales; all reported revenue came from NIH government contracts and grants.
The FDA granted the Hemopurifier Breakthrough Device designation for specified advanced or metastatic cancers and for life-threatening viruses without approved therapies. These designations do not constitute marketing approval.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue, entirely government contract/grant revenue | $659,104 | $650,187 |
| Operating expenses | $8,549,023 | $6,580,175 |
| Operating loss | $(7,889,919) | $(5,929,988) |
| Net loss attributable to common stockholders | $(7,886,709) | $(6,373,948) |
| Basic and diluted loss per share | $(0.65) | $(1.87) |
| Operating cash flow | $(6,764,940) | $(5,197,608) |
| Financing cash flow | $7,128,342 | $11,125,979 |
Research and development expense increased to approximately $2.072 million from $927,000. Operating expenses rose about $1.969 million, mainly from payroll and related expense (+$1.152 million) and general and administrative expense (+$908,000). Payroll expense included approximately $445,000 of severance accrual for the former CEO. FY2021 net loss was lower per share despite the larger net loss, alongside a substantial increase in weighted-average shares outstanding (12.09 million versus 3.41 million).
At March 31, 2021, cash was $9.862 million, working capital was $8.977 million, total assets were $10.669 million, and total liabilities were $1.375 million. Cash and restricted cash together were $9.908 million. The company reported no convertible notes outstanding; remaining liabilities included lease obligations. Management expected cash on hand, together with funds raised in June 2021, to support operations for at least 12 months from the financial statements’ issuance date.
FY2021 financing included $7.261 million net proceeds from sales of 2.686 million shares under the prior at-the-market program. The company reported no off-balance-sheet arrangements. No gross margin is provided; the filing reports no product revenue.
Material changes and subsequent events
- Revenue increased only $8,917 year over year and remained grant- and contract-dependent. The Breast Cancer Grant contributed $188,444 in FY2021 as previously deferred revenue was recognized; the new University of Pittsburgh subaward contributed $34,233.
- Operating cash use increased approximately $1.567 million. Financing cash provided fell from $11.126 million to $7.128 million.
- The FY2020 comparison included a $447,011 debt-extinguishment loss and a $51,190 gain related to warrant exchanges; neither recurred in FY2021. Convertible notes had been repaid in July 2019.
- In June 2021, after year-end, the company reported approximately $4.948 million net ATM proceeds, approximately $12.425 million gross proceeds from a registered direct offering, and $820,938 from cash warrant exercises. These transactions issued additional shares and are not included in FY2021 year-end cash.
Outlook, risks, and unusual items
- Clinical and regulatory: The head-and-neck cancer early-feasibility study with pembrolizumab was intended to enroll 10–12 patients. The COVID-19 feasibility study was designed for up to 40 ICU patients at up to 20 U.S. centers. The filing describes sites preparing to enroll, but elsewhere describes the cancer study as recruiting and treating patients; current enrollment status should be confirmed. Neither indication had FDA marketing approval; the company expected a demanding PMA pathway.
- Funding and dilution: The company has never been profitable, expects continuing losses and negative cash flows, and states that significant additional financing will be needed for operations, trials, and development. Equity financing may materially dilute existing holders. The runway statement is management’s estimate, not a guarantee.
- Supply and execution: A late-2020 quality review found a critical supplier component did not meet specifications. No affected devices were released, but resolution and alternative-supplier qualification could delay trials. Several key components have limited suppliers.
- COVID-19: Management had not experienced significant disruption to date but could not estimate future effects on trial timelines, manufacturing, operations, or capital access.
- Governance and controls: The SEC temporarily suspended trading in the company’s stock for ten days in February 2020 amid concerns about third-party promotional information and unusual market activity; the company said the investigation’s outcome and impact were uncertain. Management concluded disclosure controls and internal control over financial reporting were effective, although a risk-factor passage refers to mitigating a material weakness; the filing does not clearly reconcile those statements.
- Other risks: Commercial success depends on clinical efficacy and safety, regulatory approval, reimbursement, manufacturing scale-up, intellectual-property protection, and competition. The company also disclosed product-liability exposure and limited insurance. No pending or threatened legal proceedings were reported. The auditor issued an unqualified opinion and identified no critical audit matters.
Important facts for investors to verify
- Current cash runway and subsequent cash burn, including the impact of the June 2021 financings and additional share issuance.
- Enrollment, treatment, safety, and outcome status for the cancer and COVID-19 studies, and any updated regulatory milestones.
- Progress resolving the out-of-specification component issue and qualifying backup suppliers.
- Whether management’s internal-control conclusion and the risk-factor reference to a material weakness are consistent and reflect the same reporting period.
- Future grant and contract funding, and the company’s financing needs and expected dilution if grant revenue remains insufficient to cover operating costs.